Loading…
Taizhou Kangping Medical Science and Technology Co., Ltd. was cited for Current Good Manufacturing Practice (CGMP) violations in the production of over-the-counter drugs, rendering their products adulterated. The FDA inspection (March 10-14, 2025) identified that the company failed to establish procedures to prevent microcontamination in products labeled as sterile, specifically finding that products purported to be sterile were actually non-sterile and lacked required sterility testing. The company's April 2025 response to the FDA 483 observations was deemed inadequate because it failed to implement corrective actions necessary to bring operations into compliance with CGMP requirements.